Blog
About

190
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Use of Direct Oral Anticoagulants for Prevention of Stroke and Systemic Embolic Events in East Asian Patients with Nonvalvular Atrial Fibrillation

      , MD , 1

      Cardiovascular Innovations and Applications

      Compuscript

      anticoagulant, direct oral anticoagulant, East Asia, stroke

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          As patients in East Asia age, the prevalence of age-related and chronic disease, including nonvalvular atrial fibrillation, may increase. Although warfarin has been the primary choice of anticoagulant for the prevention of stroke and systemic embolic events, the use of direct oral anticoagulants (DOACs) is increasing. DOACs do not require monitoring of the international normalized ratio to determine the optimal dose, and have a lower potential for food and drug interactions, improved benefit-risk profiles, and a quicker onset and offset of action relative to warfarin. The pivotal phase 3 trials for each of the DOACs – dabigatran, rivaroxaban, apixaban, and edoxaban – included at least some East Asian patients. Additionally, several clinical trials were conducted specifically for East Asian patients. This review discusses patterns and predictors of anticoagulant use in East Asian patients with nonvalvular atrial fibrillation, summarizes current guideline recommendations for East Asian patients, details the primary results demonstrating the safety and efficacy of DOACs in East Asian patients relative to non–East Asian patients, provides real-world data supporting the phase 3 testing results, and addresses the clinical profile of DOACs in East Asian populations, including patients at high risk of stroke.

          Related collections

          Most cited references 62

          • Record: found
          • Abstract: not found
          • Article: not found

          2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

                Bookmark

                Author and article information

                Journal
                CVIA
                Cardiovascular Innovations and Applications
                CVIA
                Compuscript (Ireland )
                2009-8782
                2009-8618
                July 2018
                August 2018
                : 3
                : 2
                : 215-226
                Affiliations
                1Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Beijing, China
                Author notes
                Correspondence: Chang-Sheng Ma, MD, Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, Chaoyang District, Beijing 100029, People’s Republic of China, Tel.: +86-1064456412, Fax: +86-1064456078, E-mail: chshma@ 123456vip.sina.com
                Article
                cvia20170033
                10.15212/CVIA.2017.0033
                Copyright © 2018 Cardiovascular Innovations and Applications

                This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License (CC BY-NC 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc/4.0/.

                Product
                Categories
                Reviews

                Comments

                Comment on this article